| abstract |
IH:I\nterwovn\NRPortbl\DCC\SZP\18611586_l.docx-3/20/2019 Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti a4p7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-a4p7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-a4p7 antibody in vivo. |